Prevention of tuberculosis in Bacille Calmette–Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine whether a multiple-dose series of an inactivated whole cell mycobacterial vaccine, Mycobacterium vaccae, can prevent HIV-associated tuberculosis. DESIGN AND METHODS: The DarDar trial was a randomized, placebo-controlled, double-blind trial. The study was carried in an outpatient facility in Dar es Salaam, Tanzania. HIV-infected patients with CD4 cell counts of at least 200 cells/microl and a Bacille Calmette-Guérin scar were chosen for the study. The intervention was carried out by random 1:1 assignment to five intradermal doses of M. vaccae or placebo. Tuberculin skin tests were performed, and patients with reactions of at least 5 mm were administered isoniazid for 6 months. The main outcome measures were disseminated (primary endpoint), definite, and probable tuberculosis (secondary endpoints). RESULTS: Two thousand thirteen individuals were randomized (1006 to M. vaccae, 1007 to placebo) and followed every 3 months for a median of 3.3 years. The trial was terminated early because of slow accrual of cases of disseminated tuberculosis and significant protection against definite tuberculosis. Hazard ratios were disseminated tuberculosis 0.52 (95% confidence interval 0.21-1.34; seven cases in M. vaccae, 13 cases in placebo; log-rank P = 0.16), definite tuberculosis 0.61 (95% confidence interval 0.39-0.96; 33 cases in M. vaccae, 52 cases in placebo; P = 0.03), and probable tuberculosis 1.17 (95% confidence interval 0.76-1.80; 48 cases in M. vaccae, 40 cases in placebo; P = 0.46). Immunization was well tolerated, with no adverse effect on CD4 cell count or HIV viral load, and no increase in the rate of serious adverse events. CONCLUSION: Administration of a multiple-dose series of M. vaccae to HIV-infected adults with childhood Bacille Calmette-Guérin immunization is safe and is associated with significant protection against definite tuberculosis. These results provide evidence that immunization with a whole cell mycobacterial vaccine is a viable strategy for the prevention of HIV-associated tuberculosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gandhi, N. R., Moll, A., Sturm, A. W., Pawinski, R., Govender, T., Lalloo, U., Zeller, K., Andrews, J., & Friedland, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69573-1 · Cited by 1,732 · cited 1×
“Disease due to multiple-drug resistant (MDR) TB and extensively-drug resistant (XDR) TB has also fueled the global epidemic [8–10].”
BackgroundVariation in protection by BCG: implications of and for heterologous immunity
Fine, P. E. M. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92348-9 · Cited by 1,380 · cited 1×
“, infection with nontuberculous mycobacteria protects against TB) [25–27].”
BackgroundKlugman, K. P., Madhi, S. A., Huebner, R. E., Kohberger, R., Mbelle, N., & Pierce, N. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035060 · Cited by 1,009 · cited 1×
“Vaccinebased prevention of pneumococcal disease has been demonstrated in a placebo-controlled trial in HIVinfected children [41].”
Colditz, G. A., Berkey, C. S., Mosteller, F., Brewer, T. F., Wilson, M. E., Burdick, E., & Fineberg, H. V. (1995) · Pediatrics · doi:10.1542/peds.96.1.29 · Cited by 763
Global Incidence of Multidrug‐Resistant Tuberculosis
Zignol, M., Hosseini, M. S., Wright, A., Weezenbeek, C. L., Nunn, P., Watt, C. J., Williams, B. G., & Dye, C. (2006) · The Journal of Infectious Diseases · doi:10.1086/505877 · Cited by 524
Brandt, L., Feino Cunha, J., Weinreich Olsen, A., Chilima, B., Hirsch, P., Appelberg, R., & Andersen, P. (2002) · Infection and Immunity · doi:10.1128/iai.70.2.672-678.2002 · Cited by 453 · cited 1×
“BCG is also ineffective for boosting immunity in those who received the vaccine in childhood [14–16].”
Whalen, C. C., Johnson, J. L., Okwera, A., Hom, D. L., Huebner, R., Mugyenyi, P., Mugerwa, R. D., Ellner, J. J., Nsubuga, P., Vjecha, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371201 · Cited by 396 · cited 1×
“Definite TB, defined here as a secondary endpoint, is the usual primary endpoint in trials for the prevention of TB [3,45], and protection was significant against this rigorously defined and clinically meaningful endpoint.”
Lawn, S. D., Myer, L., Bekker, L.-G., & Wood, R. (2006) · AIDS · doi:10.1097/01.aids.0000238406.93249.cd · Cited by 363
Long-term Efficacy of BCG Vaccine in American Indians and Alaska Natives: A 60-Year Follow-up Study
Aronson, N. E., Santosham, M., Comstock, G. W., Howard, R. S., Moulton, L. H., Rhoades, E. R., & Harrison, L. H. (2004) · JAMA · doi:10.1001/jama.291.17.2086 · Cited by 338 · cited 2×
“[46] of the 3287 persons BCG trial conducted in the western United States in the 1930s.”
Cited by
Lawn, S. D., & Zumla, A. I. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62173-3 · Cited by 751
Zumla, A., Raviglione, M., Hafner, R., & Fordham von Reyn, C. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1200894 · Cited by 698
Phase 2b Controlled Trial of M72/AS01 E Vaccine to Prevent Tuberculosis
Van Der Meeren, O., Hatherill, M., Nduba, V., Wilkinson, R. J., Muyoyeta, M., Van Brakel, E., Ayles, H. M., Henostroza, G., Thienemann, F., Scriba, T. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803484 · Cited by 413
Building a tuberculosis-free world: The Lancet Commission on tuberculosis
Reid, M. J. A., Arinaminpathy, N., Bloom, A., Bloom, B. R., Boehme, C., Chaisson, R., Chin, D. P., Churchyard, G., Cox, H., Ditiu, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30024-8 · Cited by 361
The role of vaccines in preventing bacterial antimicrobial resistance
Jansen, K. U., Knirsch, C., & Anderson, A. S. (2018) · Nature Medicine · doi:10.1038/nm.4465 · Cited by 355
Graham, S. M., Ahmed, T., Amanullah, F., Browning, R., Cardenas, V., Casenghi, M., Cuevas, L. E., Gale, M., Gie, R. P., Grzemska, M., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis008 · Cited by 325
Kaufmann, S. H., Hussey, G., & Lambert, P.-H. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60393-5 · Cited by 299
Tuberculosis Vaccines and Prevention of Infection
Hawn, T. R., Day, T. A., Scriba, T. J., Hatherill, M., Hanekom, W. A., Evans, T. G., Churchyard, G. J., Kublin, J. G., Bekker, L.-G., & Self, S. G. (2014) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00021-14 · Cited by 164
Novel approaches to tuberculosis vaccine development
Kaufmann, S. H. E., Weiner, J., & von Reyn, C. F. (2017) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2016.10.018 · Cited by 160
Metadata
- Authors
- von Reyn, C. F., Mtei, L., Arbeit, R. D., Waddell, R., Cole, B., Mackenzie, T., Matee, M., Bakari, M., Tvaroha, S., Adams, L. V., Horsburgh, C. R., & Pallangyo, K.
- Venue
- AIDS
- Published
- 2010-03-13
- Volume
- 24
- Issue
- 5
- Pages
- 675-685
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W1984979380
- Cited by
- 220
- References
- 38
- FWCI
- 13.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.